Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Daily Feed
  • Analyst Insights & IR
  • Disclosures
    • Semiconductors
    • Energy
    • Robotics
    • Bio & Healthcare
  • Toggle search form

[Disclosure] Alteogen (196170) Clarifies Media Report on ‘KRW 200B RCPS Issuance and Shinhan Securities as Lead Manager’: “Under Consideration But Unconfirmed; No Lead Manager Contract Signed”

Posted on January 20, 2025July 11, 2026 By K-STOCK Editor No Comments on [Disclosure] Alteogen (196170) Clarifies Media Report on ‘KRW 200B RCPS Issuance and Shinhan Securities as Lead Manager’: “Under Consideration But Unconfirmed; No Lead Manager Contract Signed”

Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2025-01-20

Disclosure Type: Clarification of Rumors or Media Reports (Unconfirmed)

💡 3-Second Summary

Alteogen reiterated that while it is currently pursuing a capital raise through Redeemable Convertible Preferred Shares (RCPS), no specific terms have been finalized, and it has not signed a lead manager agreement with Shinhan Investment & Securities.

📊 1. [Key Disclosure Content & Major Figures Summary]

  • Target Media Report: The article published by Seoul Finance on November 21, 2024, titled “Alteogen, Kosdaq’s No. 1 by Market Cap, to Issue KRW 200B in RCPS… Shinhan Securities Selected as Lead Manager.”
  • Company’s Official Position (Fact Summary):
    • Funding Progress Status: The company is indeed pursuing financing options, including the potential issuance of RCPS. However, no concrete details regarding the amount or structural terms have been finalized as of the disclosure date.
    • Lead Manager Status: The report stating that the company has signed a lead manager contract with Shinhan Investment & Securities is entirely inaccurate.
  • Disclosure History: This is the second ‘unconfirmed’ follow-up update, following the initial clarification on November 21, 2024, and the subsequent update on December 20, 2024.
  • Future Timeline: The company will issue a revised disclosure when specific terms are finalized, or within one month (Scheduled update date: February 20, 2025).

📈 2. [Expert View: What This Disclosure Means for Investors]

  • Confirmation of Fundraising Efforts: Although the details remain ‘unconfirmed,’ the company officially acknowledged that a substantial capital raise via RCPS is actively under development. This implies that a large-scale cash injection may materialize in the near future, which could serve as a potential catalyst for future facility investments (CapEx) or clinical trial funding.
  • Managing Short-Term Information Uncertainty: By denying the specific detail of having contracted Shinhan Securities, the company effectively curbed speculative rumors in the market. Until a definitive, finalized disclosure is made, critical variables—such as the exact issuance size, issue price, and specific institutional buyers—remain fluid, meaning investors should exercise caution against premature speculative trading.
  • Investor Assessment Guide: When a company states that an event is ‘under consideration but not yet determined’ in a clarification disclosure, it typically suggests that a finalized board resolution or execution notice is highly likely to follow around the scheduled next update window (February 20). Investors should closely track the next update to evaluate how the finalized funding structure may impact shareholder value.

📝 Editor’s Comment (by K-STOCK Editor)

Alteogen’s updated response is a textbook “negotiations are ongoing, but not finalized” disclosure. The company has essentially organized the narrative: they are drafting blueprints to raise capital, but they haven’t put pen to paper with Shinhan Securities, and the exact financial terms are still being calibrated. For a large-cap biotech pioneer, major funding announcements are a double-edged sword—bringing both share dilution concerns and a cash war chest for pipeline expansion. Given the denial of the lead manager contract, management is likely negotiating behind closed doors with various institutional players to secure the most favorable terms. Investors should stay tuned for the official verdict around February 20.

📢 Disclaimer & Source Information

Source: This content was structured and newly written based on the official submitted data from the Financial Supervisory Service Electronic Disclosure System (DART).

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

🐂
BULLS
VS
🐻
BEARS

🔥 Bulls vs Bears, drop your analysis in the comments!

Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] Hanamicron (067310) Trading Suspension Due to Corporate Split
Next Post: [Disclosure] Alteogen (196170) Lifted from Investment Warning Stock; Designated as Investment Caution Stock for Jan 22 with Warning for Potential Re-designation

Related Posts

[Disclosure] Alteogen (196170) to List 40,820 Additional Shares Following Exercise of Stock Options Bio & Healthcare
[Disclosure] Alteogen (196170) Cancels Merger Between Subsidiaries Altos Biologics and Alteogen Healthcare Due to An Error in Calculating the Merger Ratio Disclosures
[Disclosure] Alteogen (196170) to Acquire 1.05M New Shares of Altos Biologics Due to Subsidiary Merger, Resulting in 62.89% Stake Disclosures
[Disclosure] Alteogen(196170) Secures Final MFDS Marketing Approval for ‘Tergase Inj.’, a Recombinant Human Hyaluronidase Disclosures
[Disclosure] Alteogen (196170) Clarifies Media Report on ‘KRW 200B RCPS Issuance and Shinhan Securities as Lead Manager’: “Under Consideration But Unconfirmed; No Lead Manager Contract Signed” Disclosures
[Disclosure] Alteogen(196170) Sets November 21 as Record Date for Extraordinary Shareholders’ Meeting Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hana Micron (067310) Lifted from Investment Warning Stock Status; Reclassified to Investment Caution on June 9 with Re-designation WarningJuly 8, 2026
  • [Discount Reversal via ADR Listing and Entry into an HBM-Led Super Cycle: SK hynix 000660]July 7, 2026
  • [Discount Narrowing via ADR Listing Momentum and Capital Allocation Diversification: SK Square 402340]July 7, 2026
  • Gaon Cable (000500): Structural Re-rating Driven by North American Infrastructure Expansion and AI Data Center Demand ShocksJuly 7, 2026
  • Hugel (145020): Passing the Trough with Q2 Earnings Surprise and Accelerated U.S. Direct Sales DeploymentJuly 7, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme